| Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa AJ Kunz Coyne, A El Ghali, D Holger, N Rebold, MJ Rybak Infectious diseases and therapy 11 (2), 661-682, 2022 | 128 | 2022 |
| Early multicenter experience with imipenem-cilastatin-relebactam for multidrug-resistant gram-negative infections N Rebold, T Morrisette, AM Lagnf, S Alosaimy, D Holger, K Barber, ... Open Forum Infectious Diseases 8 (12), ofab554, 2021 | 22 | 2021 |
| COVID-19: before the fall, an evidence-based narrative review of treatment options N Rebold, D Holger, S Alosaimy, T Morrisette, M Rybak Infectious Diseases and Therapy 10, 93-113, 2021 | 12 | 2021 |
| Risk Factors for Carbapenem-Resistant Enterobacterales Clinical Treatment Failure N Rebold, AM Lagnf, S Alosaimy, DJ Holger, P Witucki, A Mannino, ... Microbiology Spectrum 11 (1), e02647-22, 2023 | 9 | 2023 |
| Nephrotoxicity of vancomycin in combination with beta-lactam agents: ceftolozane-tazobactam vs piperacillin-tazobactam S Alosaimy, AM Lagnf, ALV Hobbs, M Mubarez, WD Kufel, T Morrisette, ... Clinical Infectious Diseases 76 (3), e1444-e1455, 2023 | 7 | 2023 |
| Standardized Treatment and Assessment Pathway Improves Mortality in Adults With Methicillin-resistant Staphylococcus aureus Bacteremia: STAPH Study S Alosaimy, AM Lagnf, T Morrisette, SCJ Jorgensen, TD Trinh, ... Open Forum Infectious Diseases 8 (7), ofab261, 2021 | 7 | 2021 |
| Clinical Characteristics associated with bacterial bloodstream coinfection in COVID-19 N Rebold, S Alosaimy, T Morrisette, D Holger, AM Lagnf, I Ansari, ... Infectious Diseases and Therapy 11 (3), 1281-1296, 2022 | 5 | 2022 |
| High-dose cefepime vs carbapenems for bacteremia caused by Enterobacterales with moderate to high risk of clinically significant AmpC β-lactamase production AJ Kunz Coyne, A El Ghali, K Lucas, P Witucki, N Rebold, DJ Holger, ... Open Forum Infectious Diseases 10 (3), ofad034, 2023 | 4 | 2023 |
| Impact of ceftolozane–tazobactam vs. best alternative therapy on clinical outcomes in patients with multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa … DJ Holger, NS Rebold, S Alosaimy, T Morrisette, A Lagnf, AC Belza, ... Infectious Diseases and Therapy 11 (5), 1965-1980, 2022 | 4 | 2022 |
| Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection: A Multicenter Observational Study N Rebold, S Alosaimy, JC Pearson, B Dionne, A Taqi, A Lagnf, K Lucas, ... Infectious Diseases and Therapy, 1-15, 2024 | 2 | 2024 |
| Oral stepdown in Gram‐positive bloodstream infections: A step in the right direction KE Caniff, N Rebold, MJ Rybak Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 43 (3 …, 2023 | 2 | 2023 |
| Vancomycin Dosing Guidelines: Where Do We Go From Here? N Rebold, M Rybak, F FIDP Policy, 2024 | 1 | 2024 |
| Updates in pulmonary drug‐resistant tuberculosis pharmacotherapy: A focus on BPaL and BPaLM DJ Holger, A Althubyani, T Morrisette, N Rebold, M Tailor Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2024 | | 2024 |
| High-dose Cefepime vs Carbapenems for Bacteremia Caused by Enterobacterales With Moderate to High Risk of Clinically Significant AmpC β-lactamase Production AJK Coyne, A El Ghali, K Lucas, P Witucki, N Rebold, DJ Holger, ... | | 2023 |
| 633. Eravacycline Use in Immunocompromised Patients: Multicenter Evaluation of Clinical and Safety Endpoints AJ Kunz Coyne, S Allosaimy, KC Molina, L Kang-Birken, AM Lagnf, ... Open Forum Infectious Diseases 9 (Supplement_2), ofac492. 685, 2022 | | 2022 |
| 1422. A Multi-Center Evaluation of Omadacycline for Multi-Drug Resistant Infections AE Ghali, AE Ghali, S Allosaimy, T Morrisette, KC Molina, JJ Frens, ... Open Forum Infectious Diseases 9 (Supplement_2), ofac492. 1251, 2022 | | 2022 |
| 679. Traditional vs. Alternative Agents in Patients with Lower Respiratory Tract Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa Susceptible … DJ Holger, AM Lagnf, AC Belza, S Alosaimy, NS Rebold, T Morrisette, ... Open Forum Infectious Diseases 9 (Supplement_2), ofac492. 731, 2022 | | 2022 |
| Panacea or oversimplification: Relating AUC and troughs N Rebold, T Lodise, MJ Rybak American Journal of Health-System Pharmacy 79 (12), 1019-1021, 2022 | | 2022 |
| 1288. Evaluation of Predictors for Clinical Success in Patients Treated with Eravacycline for Various Infections S Alosaimy, T Morrisette, AM Lagnf, K Molina, J Bouchard, T Gore, ... Open Forum Infectious Diseases 8 (Supplement_1), S733-S733, 2021 | | 2021 |
| Multicenter Real-World Experience with Eravacycline Targeted for Gram-positive Infections S Alosaimy, K Molina, SL Kang-Birken, A Lagnf, T Morrisette, K Claeys, ... 2021 ACCP VIRTUAL Annual Meeting, 2021 | | 2021 |
